Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says

Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says


Respiratory syncytial virus vial.

Manjurul | Istock | Getty Images

Vaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of hospitalizations over two seasons of the virus, according to a Centers for Disease Control and Prevention analysis. 

A CDC medical officer presented the analysis, conducted by researchers at the University of Michigan, at an advisory committee meeting on Wednesday. The committee recommended that adults ages 60 and older may receive one dose of Pfizer’s or GSK’s respiratory syncytial virus shot after consulting their doctor. 

The analysis found that vaccinating one million adults 65 and older with a single dose of Pfizer’s shot may prevent 2,500 hospitalizations and 25,000 outpatient visits over two seasons of the virus.

RSV season typically lasts from October to March in the Northern Hemisphere.  

The analysis also found that vaccinating one million adults in the same age group with one dose of GSK’s shot may prevent roughly 2,300 hospitalizations and 23,000 outpatient visits. 

The estimated number of prevented outcomes is lower for adults ages 60 to 64, according to the CDC medical officer, Dr. Michael Melgar. He said that’s because there’s “less existing RSV disease” in that group for the vaccine to prevent. 

The analysis further supports the efficacy of each newly approved shot in preventing RSV, a common respiratory virus that causes cold-like symptoms in most people but more severe infections in seniors and children. 

Each year, RSV hospitalizes 60,000 to 160,000 older adults and kills 6,000 to 10,000, according to CDC data. 

Pfizer and GSK on Wednesday both presented longer-term efficacy data at the meeting, which suggested that their shots generally maintain some protection against RSV after one season of the virus. 

The analysis also suggests that the shots could reduce the burden of RSV on hospitals in the fall, when multiple respiratory viruses usually begin to spread at high levels. 

Last year, cases of RSV – along with Covid and the flu – in children and older adults overwhelmed hospitals across the nation. 



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More